Skip to content

Benzonatate

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Benzonatate does in the body

Suppressing a cough.

The idea is that the drug is a numbing agent, chemically close to the ones a dentist uses, and that swallowing it lets it reach the sensors in your airways and deaden them, so they stop sending the signal that triggers a cough. That is what the label says and it is what has been said since 1958. What has never been done is a measurement in a person showing those sensors being deadened, or a properly sized trial showing that people cough less on it than on a dummy capsule.

What happened in people

Modern evidence for cough relief is weak, while accidental ingestion has killed young children within an hour.

Reviewed first-read answer

Where this came from

A person wrote this and a reviewer approved it against this exact record. It carries no effect size.

A reviewer approved this against this record. The reviewed-claim record carrying the exact population and effect size does not exist yet.

No source is stored against this line.

The limit that matters most

Its claimed numbing action in human airways has never been directly measured.

Where it acts
Stated on the label as the stretch receptors of the respiratory passages, lungs and pleura — a site asserted in 1958 and not confirmed by direct human measurement since
Kind of result
The kind of result is not recorded
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · 5P4DHS6ENR · read 2026-08-29

Where each sentence above came from

No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.

Shown as the opening line on this page.

The limit a reviewer approved as the one that matters most here.

The four opening statements run to 113 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Biomarker

A biomarker is a number from a test that stands in for something about health.

A picture of it, and where the picture fails

A biomarker is like a fuel gauge.

Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.

What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.

A measurable indicator used as a substitute for a clinical outcome of interest.

Placebo

A placebo is a dummy treatment given so the real one can be compared with it.

A picture of it, and where the picture fails

A placebo is like a blank control in an experiment.

Where that stops being true. A blank does nothing. People given a placebo often do get better.

What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.

An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.

Comparator

A comparator is whatever the treatment was measured against.

A picture of it, and where the picture fails

It is like the other runner in a race.

Where that stops being true. A race has one winner. A study can show both arms improved.

What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.

The control condition against which the experimental intervention is assessed.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Effectiveness, tolerability and safety of benzonatate across all identified original research

The study did not show it

Who was studied
Costantino 2023 systematic review (Ann Pharmacother 57:1221-1236)
How many people
37
Study design
Systematic review of four databases, January 1956 to August 2022
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
No pooled estimate. 21 cohort studies, 5 experimental studies and 11 case studies or series; quality assessment flagged high risk of bias throughout
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. The sample size given here is the number of studies, not participants. No adequately powered randomised placebo-controlled trial was identified in sixty-six years of literature.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral soft gelatin capsule (100 mg and 200 mg) containing the drug as a liquid

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

Rate of serious adverse effects — seizure, ECG change, coma or CNS depression, or death

The study showed what it set out to show

Who was studied
Cicci 2025 poison centre review (Clin Toxicol 63:488-494)
How many people
265
Study design
Retrospective single-centre case review, 2000 to 2019
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
22% of 106 intentional exposures had at least one serious adverse effect and 38% were hospitalised, against 0.7% and 2% of 143 unintentional exposures; 0 of 77 unintentional paediatric exposures had a serious effect; 2 deaths, both intentional
Repeated elsewhere
Partially Replicated

What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.

The limits of this study, and where it came from

Main limit. Single regional poison centre, so ascertainment is partial and the denominator of total exposures is unknown. No standard treatment guideline for benzonatate toxicity exists.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral soft gelatin capsule (100 mg and 200 mg) containing the drug as a liquid

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

What we know
RNAWiki holds 2 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What it changes in the bodyRead from sources, not yet reviewed

The path through the body

From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.

  1. Start

    Benzonatate

    What a person takes: Oral soft gelatin capsule (100 mg and 200 mg) containing the drug as a liquid.

    The measurement behind this step

    Must be swallowed whole. The contents are an oily local anaesthetic; releasing them in the mouth produces rapid oropharyngeal numbness and can cause choking. The label instructs patients not to break, chew, dissolve, cut or crush the capsule, and not to take two doses at once if one is missed.

  2. Getting in

    An oil inside a soft capsule

    Unlike most tablets, this drug is a liquid. It is held inside a gelatin shell that has to reach the stomach intact, because if it leaks in the mouth it numbs the throat.

    Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.

    The measurement behind this step

    Benzonatate is a nine-unit polyethylene glycol ester of p-(butylamino)benzoic acid, an oily liquid formulated in soft gelatin capsules of 100 or 200 mg. The label instructs that capsules be swallowed whole and never broken, chewed, dissolved, cut or crushed.

  3. Reaching the cell

    Absorbed and distributed within about a quarter of an hour

    The label puts onset at fifteen to twenty minutes and duration at three to eight hours. That is also, exactly, how quickly a poisoned child becomes symptomatic.

    Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.

    The measurement behind this step

    The label states onset within 15 to 20 minutes and effect lasting 3 to 8 hours, and notes that drugs of the para-aminobenzoate anaesthetic type are generally well absorbed after ingestion. The same 15-to-20-minute figure appears in the Overdosage section as the time to first signs of poisoning.

  4. What it acts on

    The asserted step: numbing the airway stretch sensors

    The label says the drug reaches the sensors in the airways, lungs and lining of the chest and dampens their activity, so the cough reflex is stopped at its source. No published measurement shows this happening.

    Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.

    The measurement behind this step

    The Clinical Pharmacology section asserts peripheral anaesthesia of stretch receptors in the respiratory passages, lungs and pleura. No recording of slowly or rapidly adapting airway afferent firing on benzonatate has been published, and the label carries no Clinical Studies section.

  5. The change it makes

    What the chemistry actually predicts

    The active end of the molecule is the same chemical family as dental anaesthetics. Those work by blocking the sodium channels nerves use to fire, and that is what happens in overdose — first excitation, then seizures, then collapse.

    Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.

    The measurement behind this step

    The label places the drug in the para-aminobenzoic acid anaesthetic class alongside procaine and tetracaine. Toxicology attributes its systemic effects to voltage-gated sodium channel blockade by a tetracaine-like metabolite, which accounts for the reported sequence in overdose: central nervous system stimulation, clonic convulsions, then profound depression, with prolonged QT interval, ventricular dysrhythmias and cardiac arrest.

  6. What that does for a person

    The clinical result nobody has measured against a placebo

    People are prescribed it for cough and many say it helps. In sixty-six years of literature, a systematic search of four databases found no adequately sized randomised comparison against a dummy capsule.

    Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.

    The measurement behind this step

    The 2023 systematic review identified 37 articles from 1956 to 2022 — 21 cohort studies, 5 experimental studies and 11 case studies or series — with quality assessment flagging high risk of bias from limited sample size, data collection, generalisability and study design throughout.

  7. What that does for a person

    The safety profile that exists is the poisoning profile

    Because there are no trials, what is known about its harms comes almost entirely from overdose reports and poison centre records rather than from controlled comparison.

    Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.

    The measurement behind this step

    The systematic review notes that safety is primarily assessed in terms of toxicity due to overdose or inappropriate use. Twenty years of one poison centre’s records give 22% serious adverse effects among 106 intentional exposures against 0.7% among 143 unintentional ones, with two deaths, both intentional.

No suggested links are held for this record, so nothing is hidden from this path.

What we know
The record describes 6 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Adults and children over ten, on prescription. It must never be within reach of a young child: accidental ingestion has killed children under ten within an hour.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

Where the result stopped carrying

  • The only systematic review concluded the approval rests on evidence that would not survive current regulatory review
  • Accidental ingestion has killed children under ten, with death reported within one hour, and the FDA added this to the label
  • Chewing or sucking the capsule has caused bronchospasm, laryngospasm and cardiovascular collapse requiring vasopressors
  • No paediatric or adult placebo-controlled cough-count trial has ever been published for a drug approved sixty-eight years ago
  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Oral soft gelatin capsule (100 mg and 200 mg) containing the drug as a liquid

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S6.

No source is stored against this line.

What is in the pack

Must be swallowed whole. The contents are an oily local anaesthetic; releasing them in the mouth produces rapid oropharyngeal numbness and can cause choking. The label instructs patients not to break, chew, dissolve, cut or crush the capsule, and not to take two doses at once if one is missed.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeRead from sources, not yet reviewed

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Worth asking a clinician aboutWritten into the record from the studies named on this page

Severe hypersensitivity reactions including bronchospasm, laryngospasm and cardiovascular collapse have been reported, possibly related to local anaesthesia from sucking or chewing the capsule, some requiring vasopressors. Isolated reports of bizarre behaviour, mental confusion and visual hallucinations in patients taking it with other drugs. Accidental ingestion has caused death in children below age 10, with symptoms at 15 to 20 minutes and death within one hour; overdose produces convulsions, coma, cerebral oedema and cardiac arrest, and central nervous system stimulants must not be used in treatment. The label caps a single dose at 200 mg and a total daily amount at 600 mg, and states that fatal overdose can occur in adults. Pregnancy Category C with no animal reproduction studies conducted.

Nobody counted how many people took this and were fine, so this cannot be turned into a rate.

Where this came from

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Oral soft gelatin capsule (100 mg and 200 mg) containing the drug as a liquid

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

The contents are an oily local anaesthetic; releasing them in the mouth produces rapid oropharyngeal numbness and can cause choking. The label instructs patients not to break, chew, dissolve, cut or crush the capsule, and not to take two doses at once if one is missed.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on which forms are sold and how they compare.

No source is stored against this line.

What is recorded as being sold

  • 145 products list this as an active ingredient in the United States drug directory. 145 of them contain it and nothing else.

    FDA National Drug Code directory · 72162-1316 · read 2026-08-29

  • They are sold as capsule, capsule, liquid filled, liquid and powder, taken oral.

    FDA National Drug Code directory · 72162-1316 · read 2026-08-29

  • The regulator's established pharmacologic class for it is decreased tracheobronchial stretch receptor activity [pe] and non-narcotic antitussive [epc].

    FDA National Drug Code directory · 72162-1316 · read 2026-08-29

  • 112 published labels name it as an active ingredient. 112 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · a2f6acff-70ff-79f1-e053-2a95a90a6005 · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · a2f6acff-70ff-79f1-e053-2a95a90a6005 · read 2026-08-29

  • Benzonatate is oral at HOW SUPPLIED Benzonatate Capsules, USP are available as: 100 mg (oval, yellow) soft gelatin capsules with imprint “A1”., recorded as fda label in effect 2024-10-23 in the United States.

    US prescribing information · 199a42ae-4d19-4e68-934d-dabd27084988 · read 2026-08-30

  • Recorded price in US: 0.06878–0.10208 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 39 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of Benzonatate studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

Claims that go past the evidence

Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.

Goes past the evidence

That the drug anaesthetises airway stretch receptors — asserted in labelling since 1958 with no published measurement of those receptors

Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.

The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.

What would change this

A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.

RNAWiki has not yet published a reviewed conclusion for this use.

Goes past the evidence

That it relieves cough better than a matched placebo capsule — no adequately sized randomised comparison exists

Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.

The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.

What would change this

A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.

RNAWiki has not yet published a reviewed conclusion for this use.

Goes past the evidence

That continued prescription-only marketing reflects a maintained regulatory judgement of efficacy

Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.

The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.

What would change this

A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.

RNAWiki has not yet published a reviewed conclusion for this use.

Goes past the evidence

That the tetracaine chemical relationship establishes the airway mechanism rather than merely the toxicology

Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.

The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.

What would change this

A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.

RNAWiki has not yet published a reviewed conclusion for this use.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Benzonatate are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

Every line above can be traced to the study named beside it. Follow the link and read it.

The only systematic review of the drug says its approval would not survive current review
In plain words
Researchers searched four databases for every study of this drug published since 1956. They found thirty-seven, none of them a properly sized randomised trial, and most of them small, old or case reports. Their conclusion was that the evidence behind its approval would not stand up today.
What was measured
Systematic search of four databases, 1956 to 2022 — count and design of all identified studies
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
A systematic review searched PubMed, Embase, the Cochrane Library and Scopus for original research on the effectiveness, tolerability and safety of benzonatate from January 1956 through August 2022. Screening yielded 37 articles: 21 cohort studies, 5 experimental studies and 11 case studies or series. The authors record that initial clinical studies exploring therapeutic benefit collected data from very small populations in limited clinical settings, that safety is primarily assessed in terms of overdose or inappropriate use rather than in trials, and that quality assessment raised concerns for high degrees of bias related to limited sample size, data collection, generalisability and study design. Their stated conclusion is that rising safety concerns should bring closer scrutiny upon the prescription of benzonatate, "whose approval is founded upon evidence that would not stand up to current regulatory review."
Source
Costantino RC, Leonard J, Gorman EF, Ventura D, Baltz A, Gressler LE. Ann Pharmacother 2023;57:1221-1236
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
contested
Review state
Written into the record, not signed off as a reviewed claim
Accidental ingestion has killed children under ten within an hour
In plain words
The capsules are soft, shiny and yellow, and a small child who swallows them can be dead within an hour. Symptoms start in fifteen to twenty minutes. This is written on the label.
What was measured
Time from ingestion to symptom onset and to death, as recorded in labelling
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
The Warnings section of the label states that accidental ingestion of benzonatate resulting in death has been reported in children below age 10, that signs and symptoms of overdose have been reported within 15 to 20 minutes, and that death has been reported within one hour of ingestion. The Overdosage section describes the sequence: rapid oropharyngeal anaesthesia with choking and airway compromise if capsules are chewed or dissolved, then central nervous system stimulation with restlessness and tremors proceeding to clonic convulsions, then profound central nervous system depression, with convulsions, coma, cerebral oedema and cardiac arrest leading to death reported within one hour. Treatment is supportive and the label directs explicitly that central nervous system stimulants must not be used. A published case describes a 13-year-old presenting with coma, seizures, hypotension, prolonged QT interval and metabolic acidosis after overdose, and records that the FDA issued a Drug Safety Communication warning of increased risk of death from accidental ingestion in children under 10 and added that information to the Warnings and Precautions section.
Source
Benzonatate prescribing information, Warnings and Overdosage sections (NDA 011210 and generics); Thimann DA, Huang CJ, Goto CS, Feng SY. J Pediatr Pharmacol Ther 2012;17:270-273
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
caution
Review state
Written into the record, not signed off as a reviewed claim
Twenty years of poison centre calls: severe in deliberate overdose, rarely otherwise
In plain words
A regional poison centre reviewed every call about this drug over twenty years. Among people who took it deliberately, more than one in five had a seizure, a heart rhythm change, coma or died. Among accidental exposures, including seventy-seven in children, almost none did.
What was measured
Rate of seizure, ECG change, coma or death by intent of exposure, across 265 poison centre cases
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
A retrospective review of all benzonatate exposures reported to the Wisconsin Poison Center from 1 January 2000 to 31 December 2019 identified 313 calls, of which 265 had complete records. Median age was 19 years and 61% were female. Of 106 intentional exposures (40%), 23 (22%) experienced at least one serious adverse effect — defined as seizure, electrocardiogram change, coma or central nervous system depression, or death — and 40 (38%) were hospitalised. Of 143 unintentional exposures (54%), one (0.7%) had a serious adverse effect and three (2%) were hospitalised. Among 77 unintentional paediatric exposures, none had a serious adverse effect and two (3%) were hospitalised. Two deaths occurred over the twenty years, both after intentional exposure. No therapeutic intervention beyond supportive care was consistently used, and the authors note that no standard treatment guideline for benzonatate toxicity exists.
Source
Cicci CD, Theobald J, Stanton M, Feldman R. Clin Toxicol 2025;63:488-494
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
verified
Review state
Written into the record, not signed off as a reviewed claim
The mechanism on the label has been asserted since 1958 and never demonstrated
In plain words
The label says the drug numbs the stretch sensors in your airways. That sentence has been in the labelling for nearly seventy years. Nobody has published a measurement of those sensors quietening in a person who has taken it.
What was measured
That the drug anaesthetises airway stretch receptors and reduces the cough reflex at its source — a mechanism asserted in labelling since 1958, chemically plausible from the tetracaine relationship, and never confirmed by a published measurement of the receptors or the reflex
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The Clinical Pharmacology section states in full: "Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours." There is no Clinical Studies section in the label. The chemical rationale is stated in Precautions — the drug is related to anaesthetics of the para-aminobenzoic acid class such as procaine and tetracaine — and the toxicology literature independently describes sodium channel blocking properties and local anaesthetic effects attributed to a tetracaine-like metabolite. What is absent is any published recording of airway afferent activity, or any human pharmacodynamic measure such as a cough challenge threshold, confirming the effect the label names.
Source
Benzonatate prescribing information, Clinical Pharmacology and Precautions sections; Thimann DA et al., J Pediatr Pharmacol Ther 2012;17:270-273
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
contested
Review state
Written into the record, not signed off as a reviewed claim
Chewing the capsule can cause laryngospasm and cardiovascular collapse
In plain words
The liquid inside the capsule is a numbing agent. If it gets into the mouth it deadens the throat within minutes, and severe reactions have followed — the airway closing, the circulation collapsing, needing drugs to restore blood pressure.
What was measured
Labelled adverse reactions attributed to release of capsule contents in the mouth
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
The Warnings section records severe hypersensitivity reactions including bronchospasm, laryngospasm and cardiovascular collapse, described as possibly related to local anaesthesia from sucking or chewing the capsule instead of swallowing it, with severe reactions requiring intervention with vasopressor agents and supportive measures. The same section records isolated instances of bizarre behaviour including mental confusion and visual hallucinations in patients taking benzonatate with other prescribed drugs. Precautions add that release of the contents in the mouth can produce temporary local anaesthesia of the oral mucosa and that choking could occur, and instruct patients to avoid food and liquid until any numbness of tongue, mouth, throat or face has resolved.
Source
Benzonatate prescribing information, Warnings and Precautions sections (NDA 011210 and generics)
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
caution
Review state
Written into the record, not signed off as a reviewed claim
It was approved four years before proof of efficacy became law, and never revisited
In plain words
The drug was approved in February 1958. In 1962 Congress required, for the first time, that a manufacturer prove a medicine works before selling it. Benzonatate was already on the market, and the standard that would have applied to a new drug was never applied to it.
What was measured
That continued marketing and prescription status reflect a maintained judgement that the drug is effective — the approval predates the efficacy requirement, and no subsequent regulatory step has re-tested it
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
NDA 011210 was approved on 10 February 1958. The Kefauver-Harris amendment of 1962 introduced the requirement for substantial evidence of effectiveness. The 200 mg Tessalon capsule now carries a Federal Register determination that it was not discontinued or withdrawn for safety or effectiveness reasons, which is a statement about why it left the market rather than about whether it works. Generic entry began in 1993 under abbreviated applications, which establish bioequivalence to the reference product and do not re-examine efficacy. The 2023 systematic review found no randomised controlled trial of adequate size in sixty-six years of literature and concluded that the evidence base underlying approval would not survive current regulatory review.
Source
Drugs@FDA, NDA 011210 (TESSALON), original approval 10 February 1958; Costantino RC et al., Ann Pharmacother 2023;57:1221-1236
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
contested
Review state
Written into the record, not signed off as a reviewed claim

Where else this substance is registered

FDA substance identifier (UNII)
5P4DHS6ENR
RxNorm concept
283417

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Reviewed first-read answer.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S6.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 17 approved applications cover products containing this substance. The earliest was NDA011210, approved 19580210 to PFIZER.

    Drugs@FDA application register · NDA011210 · read 2026-08-29

  • Marketing status on the register: discontinued and prescription.

    Drugs@FDA application register · NDA011210 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 19580210.

    FDA National Drug Code directory · 72162-1316 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

7 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

The older medicine-wide conclusion held in this record

Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.

A liquid polyethylene-glycol ester of a para-aminobenzoic acid — chemically a relative of tetracaine — approved on 10 February 1958 on the stated mechanism of anaesthetising airway stretch receptors, whose only systematic review found 37 studies comprising 21 cohorts, 5 experimental studies and 11 case reports with high risk of bias throughout, and concluded that its approval "is founded upon evidence that would not stand up to current regulatory review"; the label meanwhile records death in children under ten within one hour of accidental ingestion.

Recorded evidence blocks (5)

On the Benzonatate label: indicated for what?


"Benzonatate Capsule is indicated for the symptomatic relief of cough.": indications and usage on Benzonatate's label. DailyMed label · 07018b47-76f5-49d3-b7d3-081f82d382b2 · 2026-08-26

3 registered trials of Benzonatate — at which phases?


Registered studies posting no result
3 of 3

3 registered studies of Benzonatate: 2 phase1, 1 phase3. CLINICALTRIALS_SNAPSHOT · 2026-09-01

2 with a PubMed record

Show the evidence
  • phase1
    2
  • phase3
    1
  • completed
    2
  • unknown
    1

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Benzonatate used Benzonatate - 400 mg — over how long?


studies of Benzonatate used the recorded amount. ClinicalTrials.gov · 2026-09-01

4 recorded entries; human; also "Benzonatate - 400 mg", "Benzonatate - 600 mg", "Benzonatate 200 mg"

Show the evidence

human

  • NCT01690975
    Benzonatate - 400 mg
  • NCT01690975
    Benzonatate - 600 mg
  • NCT02207699
    Benzonatate 200 mg
  • NCT02207699
    Benzonatate 800 mg

recorded 2026-09-01 · last checked 2026-09-04

Which 2 trials of Benzonatate posted no result?


Posted no result
2 of 2 completed trials
Registrations
NCT01690975 and NCT02207699
Completion dates
oldest 2012-08; newest 2014-07
Show the evidence

Trial

  • NCT01690975
    2012-08
  • NCT02207699
    2014-07

At the median, Benzonatate's trials enrolled 68 people — anything larger?


Median enrolment
68
Largest enrolment
220
Registered trials counted
3
Where it is registered
Identifiers, relations and other names

The exact record

PubChem CID
7699
CAS number
104-31-4
RxCUI
283417
Trade name
Tessalon, Benzonatate 100 mg, Benzonatate 200 mg, TESSALON PERLES
Also called
BENZONATATE [MART.], BENZONATATE [MI], BENZONATATE [ORANGE BOOK], BENZONATATE [USP MONOGRAPH], BENZONATATE [USP-RS], BENZONATATE [VANDF], Benzonatate [WHO-DD], benzonatate [INN]
Development code
NSC-760128
Sources (5)

Sources

  • CLINICALTRIALS_SNAPSHOT K1:5P4DHS6ENR ·
  • ClinicalTrials.gov clinicaltrials.gov ·
  • drugsfda drugsfda ·
  • DailyMed label 07018b47-76f5-49d3-b7d3-081f82d382b2 ·
  • Drugs@FDA K1:5P4DHS6ENR ·

ClinicalTrials.gov — US Government work · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 5 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.